InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

- Current share price for RCE : $0.325

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$99 AUD $5.3m R&D Rebate Received 14 Jan 2026 10:37AM $0.670 $0.325 fallen by 51.49%
$99 RCE Awarded Advanced Overseas Finding up to A$85m 16 Dec 2025 9:48AM $0.600 $0.325 fallen by 45.83%
$99 Hong Kong Patent Granted for RECCE Anti-Infectives 27 Nov 2025 10:05AM $0.430 $0.325 fallen by 24.42%
$99 Positive Efficacy Data for Inhaled R327 in HAP/VAP Model 26 Nov 2025 9:50AM $0.420 $0.325 fallen by 22.62%
$99 Passing of Dr Graham Melrose - Recce founder and inventor 14 Nov 2025 4:08PM $0.435 $0.325 fallen by 25.29%
$99 Results of Meeting 5 Nov 2025 2:09PM $0.410 $0.325 fallen by 20.73%
$99 AGM Presentation 5 Nov 2025 8:58AM $0.405 $0.325 fallen by 19.75%
$99 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2025 5:21PM $0.425 $0.325 fallen by 23.53%
$99 Change of Director's Interest Notices 14 Oct 2025 6:21PM $0.430 $0.325 fallen by 24.42%
$99 Notification of cessation of securities - RCE 8 Oct 2025 8:34AM $0.420 $0.325 fallen by 22.62%
$99 Update - Notification of buy-back - RCE 8 Oct 2025 8:33AM $0.420 $0.325 fallen by 22.62%
$99 Update - Notification of buy-back - RCE 7 Oct 2025 4:41PM $0.420 $0.325 fallen by 22.62%
$99 Notice of Annual General Meeting/Proxy Form 3 Oct 2025 11:54AM $0.440 $0.325 fallen by 26.14%
$99 Patient Dosing Underway in Ph 3 Indonesia DFI Trial 25 Sep 2025 9:49AM $0.390 $0.325 fallen by 16.67%
$99 2025 Annual General Meeting 15 Sep 2025 4:46PM $0.405 $0.325 fallen by 19.75%
$99 Appendix 4G 29 Aug 2025 7:29PM $0.420 $0.325 fallen by 22.62%
$99 Annual Report to Shareholders 29 Aug 2025 7:29PM $0.420 $0.325 fallen by 22.62%
$99 Preliminary Final Report 29 Aug 2025 7:27PM $0.420 $0.325 fallen by 22.62%
$99 Preliminary Final Report 29 Aug 2025 7:27PM $0.420 $0.325 fallen by 22.62%
$99 Notification regarding unquoted securities - RCE 25 Aug 2025 7:24PM $0.430 $0.325 fallen by 24.42%
$99 R327G Highly Effective in Burn Wounds Model 12 Aug 2025 10:53AM $0.400 $0.325 fallen by 18.75%
$99 Abstract & Poster Presentation at US Military Symposium 2025 5 Aug 2025 9:44AM $0.375 $0.325 fallen by 13.33%
$99 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2025 6:18PM $0.388 $0.325 fallen by 16.13%
$99 Change in substantial holding 24 Jul 2025 9:05AM $0.363 $0.325 fallen by 10.34%
$99 Cleansing Notice 14 Jul 2025 6:10PM $0.330 $0.325 fallen by 1.52%

51 - 75 of 732 results

Page 3 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.